Xenon Pharmaceuticals Inc
Research Xenon Pharmaceuticals Inc (XENE) on Bullrun: market cap USD 5.85B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerXENE
- ExchangeNASDAQ
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 5.85B
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 102.30M
- Free cash flow-USD 89.03M
Valuation Snapshot
latest market cap is USD 5.85B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 7.50M | -USD 345.91M | -USD 279.92M | n/a | -4.36 | USD 199.16M | USD 7.94M | USD 581.76M |
| FY2024 | USD 0 | -USD 234.33M | -USD 184.46M | n/a | -3.01 | USD 142.71M | USD 9.02M | USD 754.90M |
| FY2023 | USD 0 | -USD 182.39M | -USD 156.73M | n/a | -2.73 | USD 148.64M | USD 10.90M | USD 927.92M |
| FY2022 | USD 9.43M | -USD 125.37M | -USD 103.92M | n/a | -2.06 | USD 57.24M | USD 7.85M | USD 721.50M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 5.85B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.59B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.00B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 3.47B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.47B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.61B | n/a | n/a | n/a |
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Xenon Pharmaceuticals Inc's market cap?
Xenon Pharmaceuticals Inc's market capitalization is USD 5.85B.
What does Xenon Pharmaceuticals Inc do?
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.